Californian heart start-up gets Boston's backing:
This article was originally published in Clinica
Sadra Medical, a Campbell, California company developing a device for percutaneous aortic valve replacement, has received financing from Boston Scientific and life sciences VC firm Oakwood Medical Investors in a $19m series B round. Sadra's Lotus valve, which will enter clinical evaluation within the next several months, targets patients with aortic stenosis. Around 3 million people in the US are affected with the condition, but only a small proportion receive treatment, which entails open-heart valve replacement surgery using cardiopulmonary bypass.